Hepatocellular carcinoma (HCC) is a highly aggressive disease that is usually diagnosed at an advanced stage. Advanced HCC has limited treatment options and often has a poor prognosis. For the past decade, tyrosine kinase inhibitors have been the only treatments approved for advanced HCC that have shown overall survival (OS) benefits; however, but their clinical efficacy has been limited. Recent trials have demonstrated promising advancements in survival outcomes through immunotherapy-based treatments, such as combinations of immune checkpoint inhibitors (ICIs) with other ICIs, antiangiogenic drugs, and locoregional therapies. The atezolizumab-bevacizumab and durvalumab-tremelimumab (STRIDE) regimen has significantly improved survival rates as a first-line treatment and has become the new standard of care. Therefore, combined treatments for advanced HCC can result in better treatment outcomes owing to their synergistic effects, which requires a multidisciplinary approach. Ongoing studies are examining other therapeutic innovations that can improve disease control and OS rates. Despite improvements in the treatment of advanced HCC, further studies on the optimal treatment selection and sequences, biomarker identification, combination approaches with other therapies, and development of novel immunotherapy agents are required. This review presents the current treatment options and clinical data of the ICI-based combination immunotherapies for advanced HCC from a multidisciplinary perspective.
Citations
Citations to this article as recorded by
Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports Kyeong-Min Yeom, Young-Gi Song, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim Medicina.2024; 60(1): 157. CrossRef
Hepatocellular Carcinoma: Advances in Systemic Therapy Insija Ilyas Selene, Merve Ozen, Reema A. Patel Seminars in Interventional Radiology.2024; 41(01): 056. CrossRef
Background/Aim s: Although the Barcelona Clinic Liver Cancer staging system seems to underestimate the impact of curative-intent surgical resection for multifocal hepatocellular carcinoma (HCC), recent studies have indicated favorable results for the surgical resection of multiple HCC. This study aimed to assess clinical outcomes and feasibility of surgical resection for multifocal HCC with up to three nodules compared with single tumor cases.
Methods Patients who underwent surgical resection for HCC with up to three nodules between 2009 and 2020 were included, and those with the American Joint Committee on Cancer (AJCC) 8th edition, T1 and T4 stages were excluded to reduce differences in disease distribution and severity. Finally, 81 and 52 patients were included in the single and multiple treatment groups, respectively. Short- and long-term outcomes including recurrence-free survival (RFS) and overall survival (OS), were evaluated.
Results All patients were classified as Child-Pugh class A. RFS and OS were not significantly different between the two groups (P=0.176 and P=0.966, respectively). Multivariate analysis revealed that transfusion and intrahepatic metastasis were significantly associated with recurrence (P=0.046 and P=0.005, respectively). Additionally, intrahepatic metastasis was significantly associated with OS (hazard ratio, 1.989; 95% confidence interval, 1.040-3.802; P=0.038).
Conclusions Since there was no significant difference in survival between the single and multiple groups among patients with AJCC 8th stage T2 and T3, surgical resection with curative intent could be considered with acceptable long-term survival for selected patients with multiple HCC of up to three nodules.
Non-alcoholic fatty liver disease (NAFLD), one of the most common causes of liver disease, is an increasingly common cause of hepatocellular carcinoma (HCC). Several demographic, clinical, and genetic factors contribute to HCC risk in NAFLD patients, which may inform risk stratification scores. Proven efficacious approaches to primary prevention approach in patients with non-viral liver disease remain an area of need. Semi-annual surveillance is associated with improved early tumor detection and reduced HCC-related mortality; however, patients with NAFLD have several challenges to effective surveillance, including under-recognition of at-risk patients, low surveillance utilization in clinical practice, and lower sensitivity of current tools for early-stage HCC detection. Treatment decisions are best made in a multidisciplinary fashion and are informed by several factors including tumor burden, liver dysfunction, performance status, and patient preferences. Although patients with NAFLD often have larger tumor burden and increased comorbidities compared to counterparts, they can achieve similar post-treatment survival with careful patient selection. Therefore, surgical therapies continue to provide a curative treatment option for patients diagnosed at an early stage. Although there has been debate about the efficacy of immune checkpoint inhibitors in patients with NAFLD, current data are insufficient to change treatment selection based on liver disease etiology.
Citations
Citations to this article as recorded by
Overnutrition and Lipotoxicity: Impaired Efferocytosis and Chronic Inflammation as Precursors to Multifaceted Disease Pathogenesis Vivek Mann, Alamelu Sundaresan, Shishir Shishodia Biology.2024; 13(4): 241. CrossRef
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Liver Cancer.2024; : 1. CrossRef
Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease Jeong-Ju Yoo, Man Young Park, Eun Ju Cho, Su Jong Yu, Sang Gyune Kim, Yoon Jun Kim, Young Seok Kim, Jung-Hwan Yoon Journal of Clinical Medicine.2023; 12(9): 3336. CrossRef
Reply: Validation of MELD 3.0 scoring system in East Asian patients with cirrhosis awaiting liver transplantation Jeong-Ju Yoo, Sang Gyune Kim Liver Transplantation.2023; 29(11): E38. CrossRef
Unraveling the Janus-Faced Role of Autophagy in Hepatocellular Carcinoma: Implications for Therapeutic Interventions Thi Ha Nguyen, Tuan Minh Nguyen, Dinh Thi Minh Ngoc, Taesik You, Mi Kyung Park, Chang Hoon Lee International Journal of Molecular Sciences.2023; 24(22): 16255. CrossRef
Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study Ji Kim, Hee-Chul Nam, Chang-Wook Kim, Hee Cho, Jae-Sung Yoo, Ji Han, Jeong Jang, Jong Choi, Seung Yoon, Hyun Yang, Si Bae, Suho Kim, Jung Oh, Ho Chun, Chang Jeon, Jaegyoon Ahn, Pil Sung Cancers.2023; 15(17): 4233. CrossRef
A nationwide study on the current treatment status and natural prognosis of hepatocellular carcinoma in elderly Jeong-Ju Yoo, Jayoun Lee, Gi Hong Choi, Min Woo Lee, Dong Ah Park Scientific Reports.2023;[Epub] CrossRef
Hepatocellular carcinoma (HCC) is a cytotoxic chemotherapy-resistant tumor and most HCCs arise in a background of liver cirrhosis of various causes. Although the IMBrave150 trial showed remarkable advancements in the treatment of unresectable HCC with atezolizumab plus bevacizumab (AteBeva), therapeutic outcomes were unsatisfactory in more than half of the patients. Accordingly, many ongoing trials combine conventional modalities with new drugs such as immune checkpoint inhibitors for better treatment outcomes, and they are expected to benefit patients with limited responses to conventional treatment. Here, two patients with advanced stage HCC with preserved liver function and good performance status showed partial response after treatment with combination or sequential therapy of AteBeva, hepatic arterial infusion chemotherapy, radiation therapy, and transarterial chemoembolization. These findings indicate the efficacy of multidisciplinary treatment against advanced HCC. Additional studies are required to establish optimal treatment strategies.
Citations
Citations to this article as recorded by
Complications of immunotherapy in advanced hepatocellular carcinoma Young-Gi Song, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim Journal of Liver Cancer.2024; 24(1): 9. CrossRef
Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab Tae Hyun Kim, Bo Hyun Kim, Yu Ri Cho, Young-Hwan Koh, Joong-Won Park Journal of Liver Cancer.2023; 23(2): 330. CrossRef
Is multidisciplinary treatment effective for hepatocellular carcinoma with portal vein tumor thrombus? Won Hyeok Choe Journal of Liver Cancer.2022; 22(1): 1. CrossRef
The incidence of hepatocellular carcinoma (HCC) is geographically heterogeneous depending on the underlying liver disease. Moreover, the decisions and recommendations about standard treatments differ between countries, especially between the East and the West. Because of the complexity of treatment decisions for the management of HCC, a multidisciplinary approach is recommended to maximize the therapeutic efficacy. External beam radiotherapy (RT) has been increasingly used to manage HCC when recommended treatments cannot be applied in real-world clinical practice. However, Western guidelines for the management of HCC do not recommend RT as a treatment option due to the lack of clinical evidence. RT has often been used more in Eastern countries than in Western countries; hence, it is necessary to review both Eastern and Western guidelines for HCC treatment regarding the recommendations about RT. In this study, the comments and potential roles of external beam RT are summarized from several treatment guidelines for the management of HCC.
Citations
Citations to this article as recorded by
Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study Bo Hyun Kim, Hee Chul Park, Tae Hyun Kim, Young-Hwan Koh, Jung Yong Hong, Yuri Cho, Dong Hyun Sinn, Boram Park, Joong-Won Park JHEP Reports.2024; 6(4): 100991. CrossRef
Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy Sang Min Yoon Clinical and Molecular Hepatology.2023; 29(4): 977. CrossRef
Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim Clinical and Molecular Hepatology.2023; 29(4): 1013. CrossRef
Differences in radiotherapy application according to regional disease characteristics of hepatocellular carcinoma Chai Hong Rim Journal of Liver Cancer.2021; 21(2): 113. CrossRef
Hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) have a
extremely poor prognosis. According to the Barcelona Clinic Liver Cancer guideline, sorafenib
is a standard therapy in this situation, but many clinicians still select locoregional therapy (LRT)
such as transarterial therapy, external beam radiation therapy (EBRT), even surgical resection
(SR) or combination of LRTs because the survival improvement by sorafenib is unsatisfactory.
Based on recent meta-analysis and prospective study, transarterial chemoembolization (TACE)
and transarterial radioembolization seem to be effective and safe therapeutic option that
have comparable outcome to sorafenib. Recently large nationwide studies demonstrated
that SR can be a potentially curative treatment in selected patients. Hepatic arterial infusion
chemotherapy (HAIC) can be also good option, especially in Child class B patients based
on small volume prospective studies. Moreover, multidisciplinary strategies based on the
combination of LRTs (SR plus TACE, TACE + EBRT, TACE + Sorafenib, HAIC + EBRT etc.) may
improve survival of HCC patients with PVTT. Finally we discuss individualized and tailored
treatment strategies for different clinical situations.
Citations
Citations to this article as recorded by
Progress in Non-Surgical Treatment of Primary Hepatocellular Carcinoma with Combined Portal Vein Carcinoma Thrombosis 文豪 寇 Advances in Clinical Medicine.2023; 13(07): 11779. CrossRef
Sorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits Raf kinase and the
vascular endothelial growth factor receptor intracellular kinase pathway and is the first
agent to demonstrate a statistically significant improvement in overall survival for patients
with advanced hepatocellular carcinoma (HCC). However, there were few cases of partial or
complete response reported in the previous studies. We herein report a case of dramatic
partial response in a patient who had advanced HCC with multiple lung metastasis and portal
vein thrombosis treated with sorafenib.
A 54-year-old female patient with no medical history visited our hospital complaining of both
pretibial pitting oedema for 6 months, and abdominal distension for 1 month. Computed
tomography and magnetic resonance imaging revealed an 2.3cm sized tumour at segment
2 of the liver. Her Child-Turcotte-Pugh (CTP) class was C (score 11) at the initial visit. She was
diagnosed as hepatocellular carcinoma (UICC stage II, BCLC stage D), and then she underwent
conservative treatment for 1 month. After one month of conservative treatment, her liver
function was improved to CTP class B (score 8), and then she underwent combination
treatment of transarterial chemoembolization and radiofrequency ablation. However, her
liver function was deteriorated gradually. She was transferred to other hospital for liver
transplantation eventually. (J Liver Cancer 2014;14:131-134)
Hepatocellular carcinoma is one of the most important malignancies in Korea with high mortality rates. Although current
guidelines define treatment algorithm by performance status, underlying liver function, size and number of hepatocellular
carcinoma, those are not fully reflect the complexities of patients’ characteristics and recently advanced available therapeutic
options. Treatment can be optimized by available therapeutic options based on the patients’ characteristics. Because of the
heterogeneity in presentation among patients, it is now widely accepted that management of hepatocellular carcinoma requires
multimodality and multidisciplinary treatment approaches involving hepatologists, surgeons, interventional radiologists, and
radiation oncologists. These approaches are important in improving the survival of patients with hepatocellular carcinoma.
The most important and primary endpoint in oncology research is overall survival. However, other endpoints such as
time-to-progression, time-to-recurrence and response rate have their roles in oncology trials and these endpoints are assessed by
the imaging evaluation of tumor burden. Recently published the revised version (version 1.1) of response evaluation criteria in
solid tumors (RECIST) is now the standards for the tumor response evaluation after treatment, and especially for cytotoxic
agents. However, the problems are more complicated for hepatocellular carcinoma (HCC). RECIST are mainly used for the
response evaluation of chemotherapeutic agents. However, for the treatment of HCC, there are some locoregional treatments and
molecular targeted agents, and after these treatments, tumor necrosis remains as non-enhanced tumor areas, whereas viable tumor
parts can be noted by the enhanced areas. However, these necrotic areas should be included as being tumor when we adopt the
pure anatomical criteria such as RECIST and this can distort the results of the response evaluation. For overcoming this problem,
some new criteria were introduced and their principle is the measurement of enhancing portion of the tumor only. However, these
new criteria still have limitations and functional imaging is thought to be the future problem-solving tool for the evaluation of
response for molecular targeted agents.
Tumor size is one of the most important factors for decision of therapeutic plan and prognosis of hepatocellular carcinoma
(HCC). If the diagnosis of HCC is made earlier in its small size, the prognosis is better. However the diagnosis of small HCC
is not easy because small HCC lacks the typical clinical and radiologic feature. We experienced two cases of small HCC less than
1 cm that was confirmed after first treatment.
Hepatocellular carcinoma (HCC) is one of the most important causes of cancer death in South Korea. Approximately two
thirds of the patients are diagnosed in the advanced stage with multiple metastasis and underlying liver dysfunction, so they are
not suitable to undergo curative resection. Small HCC has no consensus about diagnostic criteria but became known early stage
HCC that means good prognosis. Cases of small HCC have been increasing with the progress of diagnostic methods. We
experienced a case of incidentally found small HCC less than 1 cm from liver cirrhosis by liver dynamic imaging, so reported it.
A curative modality for hepatocellular carcinoma was a resection or a liver transplantation in a past decades, but nowadays
local ablation therapy like a percutaneous alcohol injection or a radiofrequency ablation is comparable with a surgical
resection. So a local ablation therapy is considered as a curative modality. Recently early detection of a small hepatocellular
carcinoma is becoming easy due to use a suveillance ultrasonography and computed tomography in a high risk patients.
Grobally, an indication for local ablation therapy is a small hepatocellular carcinoma less than 3 cm in diameter and have a
well-reserved liver function. But patients who met above indication is also controlled by a liver transplantation or a surgical
resection. So we should pay attention to a difference between treatment guidelines and a strengths and weaknesses of local
ablation therapy.
Cure by single modality for advanced hepatocellular carcinoma (HCC) is difficult. Therefore, multidisciplinary approaches are
needed to get a better outcome for advanced HCC. In this paper, we report a case of advanced HCC treated with curative surgical
resection after downstaging by hepatic arterial infusion chemotherapy (HAIC). A 50-year-old male patient had a maximum 16.0
cm sized HCC in the right lobe. He achieved a partial response after 2 cycles of HAIC with 5-FU (750 mg/m2) and cisplatin (25
mg/m2). After completion of 6 cycles, he received a curative right hepatectomy and the histopathology revealed 95% of tumor
necrosis. He is under follow-up without recurrence at 14 months of surgery. This case suggests that surgery after downstaging by
HAIC may provide good clinical outcome in advanced HCC.
Surgical resection for hepatocellular carcinoma (HCC) is one of the managements, showing improved long term survival.
Nowadays, it is being accepted as the main curative treatment. However, the biggest problem we used to face is that surgery
cannot be applied at the point of presentation in many patients due to advanced stage. Here we present a case of 54 years old
female, who had transarterial chemoembolization (TACE) and sorafenib due to advanced stage of HCC, and later underwent
curative surgery due to remarkable response. She had a CT scan of abdomen, which showed multiple huge masses. HCC was
confirmed by ultrasonography-guided liver biopsy. TACE was performed once. After TACE, the size of masses increased.
Therefore, sorafenib was administered and then continued for 9 months. As partial response was obtained at that time, surgical
resection was successfully done. In the pathological report of removed tumor, we could confirm total necrosis of tumor. Now, its
been 6 months and she is followed up without any recurrence.